NASDAQ:IART - Integra Lifesciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$51.38 +0.04 (+0.08 %)
(As of 04/26/2019 03:55 AM ET)
Previous Close$51.34
Today's Range$51.06 - $52.31
52-Week Range$42.14 - $67.50
Volume701,305 shs
Average Volume501,508 shs
Market Capitalization$4.38 billion
P/E Ratio21.23
Dividend YieldN/A
Beta0.96
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.47 billion
Cash Flow$3.6466 per share
Book Value$16.15 per share

Profitability

Net Income$60.80 million

Miscellaneous

Employees4,500
Market Cap$4.38 billion
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) released its quarterly earnings data on Wednesday, April, 24th. The life sciences company reported $0.65 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.61 by $0.04. The life sciences company had revenue of $359.69 million for the quarter, compared to analyst estimates of $361.12 million. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The company's revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.58 EPS. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Integra Lifesciences.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its FY19 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of $2.65-2.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.69. The company issued revenue guidance of $1.515-1.525 billion, compared to the consensus revenue estimate of $1.52 billion.Integra Lifesciences also updated its FY 2019 guidance to $2.65-2.72 EPS.

What price target have analysts set for IART?

12 brokerages have issued 12-month price targets for Integra Lifesciences' shares. Their forecasts range from $50.00 to $69.00. On average, they expect Integra Lifesciences' share price to reach $59.4545 in the next year. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "In the past three months, shares of Integra outperformed the industry. Integra exited the fourth quarter of 2018 on a solid note with better-than-expected numbers. The company witnessed double-digit growth in revenues and earnings for the fifth consecutive year. The company’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Benefitting from product launches and enhanced sales force performance, the company expects faster organic growth in the second half of 2019. Notably, the company is successfully executing its plans within Orthopedics and Tissue Technologies segment to expand sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Escalating costs and expenses have been a major headwind for the company. A tough competitive landscape adds to the woes." (4/24/2019)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)

Has Integra Lifesciences been receiving favorable news coverage?

Media headlines about IART stock have been trending somewhat negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Integra Lifesciences earned a news impact score of -1.1 on InfoTrie's scale. They also gave news articles about the life sciences company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include Intel (INTC), NVIDIA (NVDA), Celgene (CELG), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Align Technology (ALGN), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD) and GW Pharmaceuticals PLC- (GWPH).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.60%), Retirement Systems of Alabama (0.11%), Cambridge Trust Co. (0.02%), Virginia Retirement Systems ET AL (0.02%), Highland Capital Management LLC (0.02%) and Tibra Equities Europe Ltd (0.01%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Lisa Evoli, Rhonda Germany Ballintyn, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which institutional investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., Northwest Investment Counselors LLC, Cambridge Trust Co., Oakbrook Investments LLC and State of Alaska Department of Revenue. Company insiders that have sold Integra Lifesciences company stock in the last year include Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.

Which institutional investors are buying Integra Lifesciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Highland Capital Management LLC, Tibra Equities Europe Ltd, Los Angeles Capital Management & Equity Research Inc., BNP Paribas Arbitrage SA, Virginia Retirement Systems ET AL, Retirement Systems of Alabama and Campbell Newman Asset Management Inc.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill, Donald E Morel Jr and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $51.38.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $4.38 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  422 (Vote Underperform)
Total Votes:  789
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel